Expert Interview
Another View: Discussing the recent FDA approval of Novo's Ozempic (semaglutide) to reduce the risk of worsening kidney disease and cardiovascular death in adults with type 2 diabetes and chronic kidney disease
Ticker(s): NVO, LLYInstitution: Yale
- Clinical Professor of Medicine, Yale University & Section Chief of Nephrology at the Hospital of St. Raphael.
- Manages 500 patients with CKD.
- Speaker at many international Nephrology conferences and has followed the Ozempic data very closely.
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
